Novelty Nobility, Inc.
๐ฐ๐ทSouth Korea
- Country
- ๐ฐ๐ทSouth Korea
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)โข Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Phase 1
Recruiting
- Conditions
- Gastrointestinal Stromal TumorsSmall-cell Lung CancerAdenoid Cystic CarcinomaUveal MelanomaNeuroendocrine TumorsChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Novelty Nobility, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT06805825
- Locations
- ๐บ๐ธ
University of Michigan Hospitals, Ann Arbor, Michigan, United States
๐บ๐ธCase Comprehensive Cancer Center, Cleveland, Ohio, United States
๐บ๐ธOregon Health & Science University, Portland, Oregon, United States
News
No news found